pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 14·1 min read
save

Former FDA toxicologist says agency approved Zyn nicotine pouches without fully knowing their composition

Jul 14, 2026·read at STAT ↗RegulatoryNegative

Former FDA toxicologist Christy Leppanen alleges the agency authorized Zyn nicotine pouches without complete safety data on the pouch material.

Leppanen, who led a microplastics exposure project at the Center for Tobacco Products, says she was told the pouches melt in the mouth, but an academic at a late‑2024 public health conference suggested otherwise.

After the conference she purchased a menthol‑flavored Zyn can, performed informal tests at home-soaking the pouches in saliva, microwaving them, and crushing them-to assess whether they could shed microplastics.

The FDA allowed Zyn to be sold while its review was ongoing, and the allegations raise questions about potential gaps in the agency’s evaluation process.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “FDA authorized Zyn nicotine pouches without knowing what they were made of, says former agency scientist”

read at STAT ↗
2,603 words · retrieved Jul 14
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
CYCLE
drugs
nicotine18nicotine ER18
topics
ApprovalCardiologyHepatologyImmunologySmall MoleculeVaccines

related stories

  • 6h agoNovartis may cut around 130 in Switzerland while relocating biologics productionBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • 3d agoA winner, a loser, and a mid-stage signal from a major cardiology research conferenceSTAT
  • Aug 27FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adultsfda press
  • Aug 6Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he wasSTAT